Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients

Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed blood sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Wattenberg, Max M., Herrera, Veronica M., Giannone, Michael A., Gladney, Whitney L., Carpenter, Erica L., Beatty, Gregory L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021099/
https://www.ncbi.nlm.nih.gov/pubmed/33497362
http://dx.doi.org/10.1172/jci.insight.145389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021099/
https://www.ncbi.nlm.nih.gov/pubmed/33497362
http://dx.doi.org/10.1172/jci.insight.145389

Ejemplares similares